MIRA
INFORM REPORT
|
Report Date : |
11.01.2007 |
IDENTIFICATION DETAILS
|
Name : |
ARYSTA LIFESCIENCE CORPORATION |
|
|
|
|
Registered Office : |
St
Luke’s Tower 38/39F, 8-1 Akashicho Chuoku |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
Apr 1977 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki
Kaisha) |
|
|
|
|
Line of Business : |
Import, export, wholesale
agrochemicals, pharmaceutical intermediates |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
Yen
721.7 millions |
|
|
|
|
Status : |
Satisfactory
|
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
-- |
NAME
ARYSTA LIFESCIENCE CORPORATION
REGD NAME
Arysta LifeScience KK
MAIN OFFICE
St Luke’s Tower 38/39F, 8-1
Akashicho Chuoku Tokyo 104-0044
Tel : 03-3547-4500
Fax: 03-3547-4699
URL : http://www.arystalifescience.com
E-Mail address: info@arystalifescience.com
ACTIVITIES
Import, export, wholesale
agrochemicals, pharmaceutical intermediates
BRANCHES
OVERSEAS
Arysta LifeScience N America, Arysta
LifeScience Europe, Africa & Mid East, Arysta LifeScience S America, Arysta
LifeScience Haesom Corp (Korea), Bloomers Growers (New Zealand), Arysta LifeScience Maqyarorszy Kft (Hungary),
Callivoire (Cote D’Ivoir) (--subsidiaries)
OFFICERS
CHRISTOPHER RICHARDS, PRES Rudorf Van Houten, CFO
Masakazu Aoki, dir Masanao Aoki,
dir
John Killmer, Global Head Itaru Hori,
William Lewis, Head, N America Eric Barbedette, Head,
Yukio Arai, Head,
Yen Amount : In million Yen,
unless otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 40,363 M
PAYMENTS REGULAR CAPITAL Yen 17,000 M
TREND STEADY WORTH Yen 18,569 M
STARTED 1977 EMPLOYES 158*
*..
Group employees: about 2,300
COMMENT
TRADING
HOUSE SPECIALIZING IN AGROCHEMICALS & PHARMACEUTICAL INTERMEDIATES. FINANCIAL SITUATION CONSIDERED FAIR AND GOOD
FOR ORDINARY BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT: YEN 721.7
MILLION, 30 DAYS NORMAL TERMS. .
HIGHLIGHTS
The subject company was established by jointly
by Tomen Corp (now
FINANCIAL INFORMATION
The sales volume for Dec/2005 fiscal term amounted to Yen 40363 million, a 13.25% hike from Yen 26,729 million for irregular 9 months due to change in accounting term in the previous term. The growth rate is adjusted on a 12-month basis. The operations continued in the deficit to register Yen 4,840 million recurring loss and Yen 3,370 million net loss, respectively, compared with Yen 5,910 million recurring loss and Yen 3,476 net loss, respectively, a year ago. This is largely referred to huge investment costs and expenses for opening overseas office and acquisition of new brands.
For the term just ended Dec/2006 the
operations are believed come back to profitability but still limited to a
minimum amount post-taxes, on a 1.6% rise in turnover, to Yen 41,000 million. Acquisition of Proponit (
The financial situation is considered maintained FAIR and good for ORDINARY business engagements. Max credit limit is estimated at Yen 721.7 million, on 30 days normal terms.
REGISTRATION
Date Registered: Apr 1977
Legal Status: Limited
Company (Kabushiki Kaisha)
Authorized: 34
million shares
Issued: 34
million shares
Sum: Yen 17,000 million
Major shareholders (%): Toyota Tsusho Corp (38), Sojitz Corp (26), Olympus Capital Holdings Asia (9), Bank of Tokyo-Mitsubishi UFJ (0.7) (% are all about)
No. of shareholders: 6
Nothing detrimental is known as
to the commercial morality of executives.
OPERATION
Activities: A trading house for import, export and wholesale of agrochemicals, pharmaceuticals intermediates & materials, cosmetics raw materials, health foods, organic chemical intermediates, veterinary products including veterinary medicines & fee additives, others (--100%).
(Handling Brands)
Select (Registered), Captain, Everest (Registered), Orthene (Registered), Elevate (Registered), Clutch, Eminent, Monitor, CaptEvate, Maestro, other.
Clients: [Pharmaceutical mfrs, chemical firms,
wholesalers] Takeda Chemical Ind, Toyota Tsusho Corp, Sojitz Corp, Sumitomo Chemical, other.
No. of accounts: 1,000
Domestic areas of activities:
Nationwide
Suppliers: [Mfrs, wholesalers] Takeda Chemical Ind, Nissan Chemical Ind, Kumiai Chemical Ind, Nippon Soda Co, other.
Payment record: Regular
Location: Business area in
Bank References
Bank of Tokyo-Mitsubishi UFJ (
Aozora Bank (H/O)
Relations: Satisfactory
FINANCES
(In Million Yen)
|
Terms Ending: |
31/12/2006 |
31/12/2005 |
31/12/2004 |
|
|
Annual
Sales |
|
41,000
|
40,363
|
26,729
|
|
Recur.
Profit |
|
|
-4,840
|
-5,910
|
|
Net
Profit |
|
0 |
-3,370
|
-3,476
|
|
Total
Assets |
|
|
70,015
|
63,629
|
|
Current
Assets |
|
|
34,015
|
21,494
|
|
Current
Liabs |
|
|
14,941
|
10,351
|
|
Net
Worth |
|
|
18,569
|
15,015
|
|
Capital,
Paid-Up |
|
|
17,000
|
17,000
|
|
<Analytical
Data> |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
1.58 |
13.25
|
-2.69
|
|
|
Current Ratio |
|
.. |
227.66
|
207.65
|
|
N.Worth Ratio |
.. |
26.52
|
23.60
|
|
|
R.Profit/Sales |
|
.. |
-11.99
|
-22.11
|
|
N.Profit/Sales |
0.00 |
-8.35
|
-13.00
|
|
|
Return On Equity |
.. |
-18.15
|
-23.15
|
|
Note: The 31/12/2004 fiscal term was for irregular 9 months due to change to Jan/Dec from Apr/Mar fiscal terms. Growth rates are adjusted on a 12-month basis.
Forecast (or estimated) for the
31/12/2006 fiscal term.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|